News
-
-
-
PRESS RELEASE
Allinvest Securities Initiates Analyst Coverage on THX Pharma with Buy Recommendation
THX Pharma (Theranexus) announces analyst coverage by Allinvest Securities recognizing successful transformation into rare-disease platform with buy recommendation and 226% upside potential. Portzamparc also follows THX Pharma -
-
-
PRESS RELEASE
THX Pharma (Theranexus) and Exeltis secure EMA approval of the paediatric investigation plan (PIP) for TX01, unlocking the PUMA registration pathway
THX Pharma and Exeltis secure 10 years of European market protection for TX01 in Niemann-Pick type C disease with positive PIP approval by EMA's Paediatric Committee (PDCO), paving the way for PUMA submission -
-
PRESS RELEASE
THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
Join THX Pharma, Biocodex, and BBDF as Platinum Sponsors at the 2026 BDSRA Family Conference to provide an update on the Batten-1 program and Phase 3 study for CLN3 Batten disease -
-
